Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | The challenges of modern day immunotherapy for pharmacists

Jacob Kettle • 21 Mar 2018
HOPA 2018
General

Here, Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, shares his perspective on the different challenges surrounding the advancements made in the development of newer immunotherapy agents for pharmacists, including the need to constantly keep up to date with newly approved drugs, and being aware of their side effects on different organ systems upon administration. This video was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO.

More from Jacob Kettle

How can pharmacists approach the ‘grey area’ surrounding PD-L1 testing?
1:24
How can pharmacists approach the ‘grey area’ surrounding PD-L1 testing?
Jacob Kettle • 21 Mar 2018
Drugs with low response rates - should they always be offered to patients?
3:22
Drugs with low response rates - should they always be offered to patients?
Jacob Kettle • 21 Mar 2018
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
3:50
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
Jacob Kettle • 21 Mar 2018

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals